Tuesday, November 27, 2018

Phase 3 trial shows lanadelumab to be effective in reducing hereditary angioedema attacks

A phase 3 clinical trial finds that injections of the monoclonal antibody drug lanadelumab reduced attacks of hereditary angioedema -- a rare, potentially life-threatening disorder.

from Top Health News -- ScienceDaily https://ift.tt/2E0NpZL
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Common food preservative linked to rising suicide deaths among young people

A widely available food-preservation chemical is emerging as a disturbing factor in rising UK suicide deaths, particularly among younger peo...